Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec;9(6):635-639.
doi: 10.3892/mco.2018.1729. Epub 2018 Oct 1.

Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors

Alessandro Villanucci  1 , Ketty Tavella  1 , Laura Vannini  2 , Virginia Rossi  2 , Stefania Nobili  2 , Gianni Amunni  2 , Teresita Mazzei  2 , Enrico Mini  2
Affiliations

Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors

Alessandro Villanucci et al. Mol Clin Oncol. 2018 Dec.

Abstract

The majority of patients with ovarian cancer will experience relapse and thus require second-line therapy. While platinum-based therapies are the primary treatments for refractory disease other options are required, particularly for those with partially platinum-sensitive disease as their response rates are lower. Agents that can resensitize relapsed ovarian cancers to platinum, including trabectedin, are therefore of increasing interest. Trabectedin is a multitarget agent that has a complex, novel mechanism of action and has exhibited promising results in platinum-sensitive ovarian cancer when in combination with pegylated liposomal doxorubicin (PLD). The present study conducted retrospective analysis involving 11 cases (median age 60 years; range 45-75 years) of recurrent ovarian tumors and partial platinum sensitivity undergoing treatment with trabectedin + PLD. The cohort consisted of 7 serous carcinomas, 1 endometrial carcinoma, 2 undifferentiated carcinomas, and 1 mucinous carcinoma. Of the 11 patients, 4 exhibited a complete response, 3 achieved stable disease, and 4 had progression of disease. Mean overall survival was 32.42 months and median progression-free survival was 5.9 months. Trabectedin in combination with PLD was well tolerated in terms of gastrointestinal and hematological toxicity; Grade 3 cutaneous toxicity and grade 3 neutropenia were each observed in 18.2% of patients. There were no grade 4 events. Thus, the present study supports the use of trabectedin + PLD in patients with relapsed ovarian cancer and partial platinum sensitivity, with predictable and manageable toxicity.

Keywords: ovarian cancer; pegylated liposomal doxorubicin; recurrence; retrospective analysis; survival; trabectedin; treatment.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan-Meier estimate of OS (n=11). There were 5 patients with events; 6 patients were censored. OS, overall survival.
Figure 2.
Figure 2.
Kaplan-Meier estimate of PFS (n=11). There were 8 patients with events; 3 patients were censored. PFS, progression-free survival.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Colombo N. Optimizing treatment of the partially platinum-sensitive ovarian cancer patient. Future Oncol. 2013;9(12 Suppl):S19–S23. doi: 10.2217/fon.13.206. - DOI - PubMed
    1. Friedlander M, Trimble E, Tinker A, Alberts D, Avall-Lundqvist E, Brady M, Harter P, Pignata S, Pujade-Lauraine E, Sehouli J, et al. Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer. 2011;21:771–775. doi: 10.1097/IGC.0b013e31821bb8aa. - DOI - PubMed
    1. González-Martín A. Update on relapsed ovarian cancer treatment: From new consensus to daily clinical practice. Future Oncol. 2017;13(23s):1–9. doi: 10.2217/fon-2017-0316. - DOI - PubMed
    1. Gore ME, Fryatt I, Wiltshaw E, Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol. 1990;36:207–211. doi: 10.1016/0090-8258(90)90174-J. - DOI - PubMed
    1. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis JL., Jr Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991;9:389–393. doi: 10.1200/JCO.1991.9.3.389. - DOI - PubMed